The University of Texas Health Science Center at Tyler
15
1
2
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
40%
6 trials in Phase 3/4
10%
1 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
Role: collaborator
Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin
Role: collaborator
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
Role: collaborator
Irrisept in Emergency General Surgery Patients
Role: lead
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
Role: collaborator
A Single Ketamine Infusion Combined With Music for Suicidal Ideation
Role: lead
Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease
Role: collaborator
Investigating the Effectiveness of a Seasonal Influenza Vaccination Promotion Campaign for Members of a Non-Profit, Community-Based Health Insurance Plan: 2018-2019
Role: lead
Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease
Role: lead
Azithromycin in the Treatment of M. Avium Complex Lung Disease
Role: lead
Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
Role: lead
Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease
Role: lead
Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)
Role: lead
Tigecycline for Treatment of Rapidly Growing Mycobacteria
Role: lead
Randomized Trial of Physical Activity Self-Management Intervention for Patients With COPD
Role: lead
All 15 trials loaded